本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002688 证券简称：金河生物 公告编号：2025-067 金河生物科技股份有限公司 2025年第四次临时股东大会决议的公告 特别提示： 1、本次股东大会无否决提案的情形。 2、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 金河生物科技股份有限公司（以下简称"公司"）2025 年第四次临时股东 大会通知于 2025 年 7 月 8 日在《上海证券报》、《证券时报》、《证券日报》 《中国证券报》及巨潮资讯网（www.cninfo.com.cn）以公告方式发出。 1、召开时间 （1）现场会议召开时间：2025 年 7 月 23 日下午 14:30 （2）网络投票时间：2025 年 7 月 23 日 2、股权登记日：2025 年 7 月 16 日 3、现场会议召开地点：内蒙古自治区托克托县新坪路 71 号公司三楼会议室 4、会议表决方式：现场投票与网络投票表决相结合的方式 5、会议召集人：公司董事会 6、现场会议主持人：董事长王东晓先生 1 7、本次股东大会会议的召 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-068 金河生物科技股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、通知债权人的原因 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召开 第六届董事会第二十七次会议和第六届监事会第二十二次会议，于 2025 年 7 月 23 日召开 2025 年第四次临时股东大会，审议通过了《关于回购注销部分限制性 股 票 及 调 整 回 购 价 格 的 议 案 》 。 具 体 内 容 详 见 公 司 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）及《证券时报》《中国证券报》《证券日报》和 《上海证券报》披露的相关公告。 因公司 2023 年限制性股票激励计划首次授予第二个解除限售期部分激励对 象 2024 年个人层面业绩考核未完全达标，同时因公司 2023 年限制性股票激励计 划首次授予激励对象中 1 人因个人原因离职、3 人因退休离职，已不符合激励对 象条件，公 ...

Core Viewpoint - The veterinary raw material drug market in China is expected to grow significantly, with a projected market size of approximately 185.1 billion yuan in 2024 and around 200 billion yuan in 2025, driven by increased demand and favorable economic conditions [1][8]. Industry Characteristics and Classification - Veterinary raw material drugs are pharmacologically active substances used directly in the manufacture of veterinary drug formulations, characterized by specificity, regulatory requirements, and high technical barriers [2][4]. - They can be classified by chemical properties into synthetic raw materials, biotechnological raw materials, and natural extracts, and by usage into antimicrobial drugs, antiparasitic drugs, antipyretic analgesics, and diagnostic/treatment aids [4][5]. Current Development Status - The veterinary drug industry in China has rapidly developed, becoming a significant part of the global veterinary drug market, with a projected market size of approximately 600 billion yuan in 2024 and 635 billion yuan in 2025 [6][8]. Market Size and Growth - The veterinary raw material drug market is expected to see a growth from 185.1 billion yuan in 2024 to 200 billion yuan in 2025, reflecting a recovery in demand and controlled supply [8][10]. Market Segmentation - Antimicrobial drugs dominate the veterinary raw material drug market, holding an 84% market share, while antiparasitic drugs account for about 11% [10]. Industry Chain - The industry chain includes upstream components such as basic chemical raw materials and intermediates, midstream production of raw materials through chemical synthesis and fermentation, and downstream processing into veterinary drug formulations for livestock and pet healthcare [12]. Competitive Landscape - The veterinary raw material drug industry in China has a low concentration level, with major companies including Haisheng Pharmaceutical, Qihui Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, among others [14][16]. - The industry is experiencing a shift towards larger, more capable firms as regulatory standards improve, leading to a potential increase in market concentration [14]. Key Enterprises - Guobang Pharmaceutical reported a revenue of 1.831 billion yuan from animal health raw materials in 2024, with a gross margin of 18.86% [16]. - Haisheng Pharmaceutical achieved a revenue of 112 million yuan from raw materials in 2024, with a gross margin of 36.28% [18]. Technology Development Trends - The production of raw materials and intermediates requires significant investment in research and development to improve process technology and compete in higher-margin sectors [20].

Core Points - The company has approved the first unlock period for the reserved grant of restricted stock, allowing 11 eligible incentive recipients to unlock 500,000 shares [2][14][21] - The total share capital of the company is 771,634,398 shares, and the unlocked shares represent 0.0648% of the total share capital [2][21] - The unlock date for the restricted stock is set for December 28, 2023, with a commitment to a 12-month lock-up period, making the shares tradable on July 25, 2025 [19][21] Summary by Sections Incentive Plan Approval - The incentive plan was approved through various board meetings, with the first grant involving 123 recipients and a total of 21,620,000 shares [3][6] - The initial grant price was set at 2.59 CNY per share, later adjusted to 2.49 CNY per share [4][6] Reserved Grant Details - The reserved grant consists of 5,049,910 shares, with similar unlocking conditions as the initial grant [4] - The first unlock period for the reserved shares is set to follow the same schedule as the initial grant [4] Unlock Conditions - The board confirmed that the conditions for unlocking the first reserved grant have been met, allowing for the release of 500,000 shares to the eligible recipients [14][18] - The company will repurchase any shares that do not meet the unlock conditions due to employee departures or other disqualifying factors [18] Stock Structure Changes - Following the unlock, the total number of shares will be adjusted accordingly, with the company maintaining compliance with relevant regulations [22][24] - The board and supervisory committee have both approved the unlock conditions and the related stock repurchase actions [22][23]

证券代码：002688 证券简称：金河生物 公告编号：2025-066 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划预留授予第一个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次预留授予第一个解除限售期符合解除限售资格的激励对象 11 名， 可解除限售的限制性股票 500,000 股。 （二）金河生物科技股份有 限公司（以下简称"公司"）目前股本为 （三）本次解除限售的限制性股票限售起始日期为 2023 年 12 月 28 日，承 诺的限售期限为 12 个月，上市流通日为 2025 年 7 月 25 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》。鉴于 限售期的解除限售条件已成就，根据公司 2022 年度股东大会对董事会的授权， 公司按规定为预留授予第一个解除限售期符合解除限售资 ...

Group 1 - The company expects a net profit attributable to shareholders for the first half of 2025 to be between 127.43 million and 141.08 million yuan, representing a growth of 40% to 55% compared to 91.02 million yuan in the same period last year [2] - The growth in performance is attributed to the strong sales of veterinary chemical products, particularly the sales of the main product, chlortetracycline, in both domestic and overseas markets, with significant growth in overseas sales [2] - The company's production capacity has increased following the launch of its sixth-phase project, which has ensured supply to both domestic and international markets, contributing to higher profits [2] Group 2 - The global beef cattle industry is entering a new cyclical turning point, with average prices for ground beef in the U.S. rising nearly 12% year-on-year in June, and unprocessed beef steak prices increasing by 8%, reaching historical highs [2] - The rising prices of beef and live cattle in the U.S. are expected to boost the demand for veterinary drugs for live cattle, as local ranchers become less sensitive to drug prices due to increased profits from higher beef prices [2] - The company is the largest producer of veterinary chlortetracycline globally, with 60% to 70% of its products sold overseas, primarily in the U.S., which accounts for about two-thirds of its exports [3] Group 3 - As of July 11, 2025, the wholesale price of beef in China was 63.56 yuan per kilogram, an increase of 4.51% year-on-year, while the price of calves rose to 29.81 yuan per kilogram, up 26.37% year-on-year [4] - The decline in cattle inventory and the rising price of calves are expected to support beef prices in the second half of 2025 and into 2026, indicating a continuation of the beef cycle's prosperity [4] - The company is enhancing its leading position in the chlortetracycline market due to increased usage in large-scale farming and the development of a new animal brucellosis vaccine that has won a major procurement project [4]

金河生物科技股份有限公司 关于 2023 年限制性股票激励计划预留授予第一个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次预留授予第一个解除限售期符合解除限售资格的激励对象 11 名， 可解除限售的限制性股票 500,000 股。 证券代码：002688 证券简称：金河生物 公告编号：2025-066 （二）金河生物科技股份有限公司（以下简称"公司"）目前股本为 771,634,398 股，本次预留授予第一个解除限售期可解除限售的限制性股票 500,000 股，占公司目前总股本的 0.0648%。 （三）本次解除限售的限制性股票限售起始日期为 2023 年 12 月 28 日，承 诺的限售期限为 12 个月，上市流通日为 2025 年 7 月 25 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》 ...

Group 1 - The animal vaccine sector experienced a decline of 0.96%, ranking among the top losers in the concept sector, with companies like BioShares, Zhongmu, and Pulaike leading the declines [1][2] - Among the animal vaccine stocks, five companies saw price increases, with Luoniushan, Weilan Biology, and Dabeinong rising by 1.42%, 1.38%, and 0.73% respectively [1][2] - The animal vaccine sector faced a net outflow of 218 million yuan from main funds, with 12 stocks experiencing outflows, and six stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was BioShares, with a net outflow of 128 million yuan, followed by Xianfeng Holdings, Jinhai Biological, and Zhongmu, with net outflows of 41.99 million yuan, 26.07 million yuan, and 25.32 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Dabeinong, Luoniushan, and Weilan Biology, attracting net inflows of 34.95 million yuan, 23.76 million yuan, and 13.06 million yuan respectively [2][3] - The detailed outflow data for the animal vaccine sector shows significant declines in stock prices, with BioShares down by 5.56% and a turnover rate of 11.26% [2][3]

证券代码：002688 证券简称：金河生物 公告编号：2025-065 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个 解除限售期解除限售股份上市流通的提示性公告 （一）本次首次授予第二个解除限售期符合解除限售资格的激励对象 70 名， 可解除限售的限制性股票 4,326,000 股。 （二）金河生物科技股份有 限公司（以下简称"公司"）目前股本为 （三）本次解除限售的限制性股票限售起始日期为 2023 年 7 月 7 日，承诺 的限售期限为 24 个月，上市流通日为 2025 年 7 月 21 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议案》。鉴于 限售期的解除限售条件已成就，根据公司 2022 年度股东大会对董事会的授权， 公司按规定为首次授予第二个解除限售期符合解除限售资格的激励对象 70 名办 理限制性股票解除限售股份上市流通的相关事宜。本次可解除限售的限制性股票 一、本激励计划已履行的相关审 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-065 金河生物科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个 解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 重要内容提示： （一）本次首次授予第二个解除限售期符合解除限售资格的激励对象 70 名， 可解除限售的限制性股票 4,326,000 股。 （二）金河生物科技股份有限公司（以下简称"公司"）目前股本为 771,634,398 股，本次首次授予第二个解除限售期可解除限售的限制性股票 4,326,000 股，占公司目前总股本的 0.5606%。 （三）本次解除限售的限制性股票限售起始日期为 2023 年 7 月 7 日，承诺 的限售期限为 24 个月，上市流通日为 2025 年 7 月 21 日。 公司于 2025 年 7 月 7 日分别召开第六届董事会第二十七次会议和第六届监 事会第二十二次会议，审议通过《关于 2023 年限制性股票激励计划首次授予第 二个解除限售期及预留授予第一个解除限售期解除限售条件成就的议 ...